Amgen adds potential blockbuster drug with $3.7 bln ChemoCentryx deal
Reuters -

Amgen Inc said on Thursday it would buy ChemoCentryx Inc for $3.7 billion as the U.S. drugmaker seeks to bolster its portfolio with a newly approved potential blockbuster anti-inflammation treatment.

Related Articles

Latest in News

More from Reuters | EF:BUSINESS-FUTURE-OF-HEALTH BACT BIOPH BLR CMPNY DEAL1 HECA MRCH MRG PHAG08 PHAR PHAR08 PHAR1 PHMR AMERS US NAMER GEN HEA MEDST MTPIX PXP TOPCMB TOPNWS ChemoCentryx Amgen NASDAQ:CCXI NASDAQ:AMGN